Nxera Pharma says Neurocrine wins FDA IND clearance for Phase 2 Alzheimer’s cognition trial of NBI-1117567

• Neurocrine received FDA IND acceptance for a Phase 2 study of NBI-1117567 targeting cognition in Alzheimer’s disease in Q3 FY2026.
• No trial results were presented; the update relates to the start of a mid-stage clinical program.
• Nxera will receive a USD 10 million milestone payment, expected to be recognized as revenue in Q3 FY2026.
• The drug is an oral, muscarinic M1-preferring agonist discovered by Nxera, developed under a multi-program collaboration with Neurocrine.
• Nxera retains development and commercialization rights for the M1 receptor agonist in Japan across all indications.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nxera Pharma Co. Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608260333PRIMZONEFULLFEED1001259394) on August 26, 2026, and is solely responsible for the information contained therein.